Financial Snapshot
This section of the Fusion Pharmaceuticals InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing.
Please note: All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. Fusion Pharmaceuticals assumes no responsibility for the accuracy of this data and provides it for informational purposes only.
NASDAQFUSN
| Beta | (1.17) |
|---|---|
| Shares Outstanding | 44.8M |
| Average Volume (10 days) | 69.3K |
| Qtrly Dividend (Ann. Yield) | -- (--) |
Analyst Views
| Current Mean Recommendation | Strong Buy |
|---|
| Strong Buy | 9 | |
|---|---|---|
| Buy | 0 | |
| Hold | 0 | |
| Underperform | 0 | |
| Sell | 0 |
Recent Insider Transactions
Chau Q. Khuong Director | 42,093 Acquire Nov 11, 2022 |
|---|---|
Steven Gannon Director | 44,400 Buy Aug 11, 2022 |
John Valliant Director, Chief Executive Officer | (4,511) Sell Apr 27, 2022 |
John Valliant Director, Chief Executive Officer | (2,147) Sell Apr 26, 2022 |
John Valliant Director, Chief Executive Officer | (2,036) Sell Apr 25, 2022 |
NEVER MISS AN UPDATE
